Rxo (RXO) Cash from Financing Activities (2021 - 2026)

Rxo (RXO) has reported Cash from Financing Activities for 6 consecutive years, with $28.0 million the latest figure, recorded in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $28.0 million, up 300.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.0 million (down 98.02% YoY), and the FY2025 annual result was $1.0 million, down 99.91% from the prior year.
• Cash from Financing Activities was $28.0 million for Q1 2026 at Rxo, up from -$3.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.1 billion in Q3 2024 and troughed at -$145.0 million in Q4 2022.
• Average Cash from Financing Activities over 5 years is $52.3 million, with a median of -$3.0 million recorded in 2025.
• Year-over-year, Cash from Financing Activities tumbled 417.86% in 2022 and jumped 27225.0% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$145.0 million in 2022, then jumped by 31.03% to -$100.0 million in 2023, then jumped by 101.0% to $1.0 million in 2024, then tumbled by 400.0% to -$3.0 million in 2025, then surged by 1033.33% to $28.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $28.0 million in Q1 2026, -$3.0 million in Q3 2025, and -$3.0 million in Q2 2025.